COMPANY RESEARCHBioNTech SE
BioNTech is a Germany-based biotechnology company focused on immunotherapies and other innovative treatments. Its research includes messenger RNA technologies, engineered immune approaches and additional modalities intended for cancer and infectious diseases. The company combines internal discovery and clinical development with manufacturing capabilities and external research collaborations. BioNTech maintains investor relations materials for its Nasdaq-listed securities and publishes updates about therapeutic and vaccine development on its official website. Its platform research connects genetic medicines with oncology and infectious disease applications.
Company at a glance
Corporate information
- Company entity
- BioNTech SE
- Headquarters / principal office
- Mainz, Rhineland-PalatinateSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.
Sources (1)
- Company-managed LinkedIn profile — self-reported locationChecked 2026-11-04; source publication date retained where stated
- Founded
- 2008
Sources (1)
- The BioNTech storyNot stated
- Ownership / capital status
- Publicly tradedPublicly traded
Sources (1)
- Official corporate reference
- https://www.biontech.com/
Sources (1)
- BioNTech AboutNot stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- BioNTech SE · LinkedIn Company Page主页Not stated
- Latest financing / award identified
- 2019-10-10 · IPO (historical) · USD 150 million (excluding the overallotment option)
Sources (1)
Expected gross proceeds disclosed at pricing of the 2019 IPO; not the latest financing as of 2026.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
BioNTech is a Germany-based biotechnology company focused on immunotherapies and other innovative treatments. Its research includes messenger RNA technologies, engineered immune approaches and additional modalities intended for cancer and infectious diseases. The company combines internal discovery and clinical development with manufacturing capabilities and external research collaborations. BioNTech maintains investor relations materials for its Nasdaq-listed securities and publishes updates about therapeutic and vaccine development on its official website. Its platform research connects genetic medicines with oncology and infectious disease applications.
Nasdaq: BNTX
mRNA therapeutics · immunotherapies
oncology · infectious disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
Business, technology & evidence
- The FDA product page lists COMIRNATY as a COVID-19 mRNA vaccine from BioNTech Manufacturing GmbH.
- BioNTech is a Germany-based biotechnology company focused on immunotherapies and other innovative treatments. Its research includes messenger RNA technologies, engineered immune approaches and additional modalities intended for cancer and infectious diseases. The company combines internal discovery and clinical development with manufacturing capabilities and external research collaborations. BioNTech maintains investor relations materials for its Nasdaq-listed securities and publishes updates about therapeutic and vaccine development on its official website. Its platform research connects genetic medicines with oncology and infectious disease applications.
- SecuritiesNasdaq: BNTX
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| COMIRNATY | Project-dependent / not verified · Project-dependent / not verified | Approved (representative vaccine) | Regulatory validation applies to the named vaccine and should not be extended to other programs. |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- The pipeline is not exhaustive. Evidence for a representative program should not be attributed to the entire platform.
- BioNTech About ↗BioNTech SE · Undated
- FDA COMIRNATY product page ↗FDA · Undated
- Official issuer and R&D disclosure · BioNTech SE ↗BioNTech SE ·
- Official issuer and R&D disclosure · BioNTech SE ↗BioNTech SE ·
- Official issuer and R&D disclosure · BioNTech SE ↗BioNTech SE ·
- BioNTech SE · LinkedIn Company Page主页 ↗BioNTech SE / LinkedIn · Not stated
- The BioNTech story ↗BioNTech SE · Not stated
- BioNTech Announces Pricing of Initial Public Offering ↗BioNTech SE · 2019-10-10
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.